For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the arrival of Vyndamax and Attruby represents a genuine change. These novel therapies preserve the transthyretin protein, halting its destructive build-up and lessening the burden of the disease . Individuals are now reporting benefits in their quality of l